Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

Eric J. Jaehnig; Aranzazu Fernandez-Martinez; Tanmayi D. Vashist; Matthew V. Holt; LaTerrica Williams; Jonathan T. Lei; Chang In Moon; Beom-Jun Kim; Yongchao Dou; Haoquan Zhao; Viktoriya Korchina; Richard A. Gibbs; Donna M. Muzny; HarshaVardhan Doddapaneni; Charles M. Perou; Lisa A. Carey; Ana I. Robles; Terry Hyslop; Yujia Wen; Linda McCart; Azra Krek; Francesca Petralia; George Miles; Shyam M. Kavuri; Michael A. Gillette; D.R. Mani; Steven A. Carr; Bing Zhang; Matthew J. Ellis; Shankha Satpathy; Meenakshi Anurag

doi:10.17615/xaca-k594

Related Publications

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid , Javier Cortés , Lajos Pusztai +18 more

Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...

2020 New England Journal of Medicine 2718 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz , Chiun‐Sheng Huang , Max S. Mano +26 more

Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer...

2018 New England Journal of Medicine 2430 citations

Breast cancer

Sibylle Loibl , Philip Poortmans , Monica Morrow +2 more

Breast cancer is still the most common cancer worldwide. But the way breast cancer is viewed has changed drastically since its molecular hallmarks were extensively characterised...

2021 The Lancet 1433 citations

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid , Hope S. Rugo , Sylvia Adams +12 more

2019 The Lancet Oncology 1134 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Eric J. Jaehnig, 
                                
                                    Aranzazu Fernandez-Martinez, 
                                
                                    Tanmayi D. Vashist
                                
                                et al.
                            
                            (2025). 
                            Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. 
                            UNC Libraries
                            
                            .
                            https://doi.org/10.17615/xaca-k594

Identifiers

DOI: 10.17615/xaca-k594